Abstract:To evaluate if breast-conserving therapy achieved superior efficacy to modified radical mastectomy in patients with T1-2N1M0 breast cancer. 2776 women with T1-2N1M0 breast cancer treated from 1999 to 2013 were retrospectively reviewed. All had received lumpectomy or mastectomy and axillary lymph node dissection without neoadjuvant chemotherapy. The median age was 49 years. 2484 patients underwent modified radical mastectomy (MRM), 580 (23.3%) of them received postoperative RT (MRM + RT). 292 patients received breast-conserving surgery (BCT), all of them received postoperative RT. For the whole group, 92.7% of received postoperative chemotherapy and 4.9% received trastuzumab targeted therapy. Of the 2148 patients with ER and/or PR positive, 87.7% received hormonal therapy. Survival and recurrence rates were calculated by using the Kaplan-Meier method and compared by log-rank test. Multivariable analysis was estimated by using the Cox proportional hazards model. At a median follow-up of 59 months (range, 1-257 months), the 5-year overall survival (OS) of the BCT and MRM groups was 97.9% and 92.9% (p= 0.014), and the 5-year locoregional recurrence (LRR) was 2.3% vs 6.1% (p= 0.022). Of MRM group, the 5-year OS was 92.7% in MRM alone and 93.5% in MRM + RT (p = 0.037), and the 5-year LRR was 6.3% and 5.2%, respectively (p = 0.188). Furthermore, the 5-year OS of BCT group was significantly higher than that of MRM alone (p = 0.007), however there was no significant difference in OS between BCT and MRM + RT (P = 0.160). The 5-year LRR of BCT group was significantly lower than that of MRM alone (p = 0.016), but had no significant difference with MRM + RT (p = 0.094). Univariate analysis showed that age ≤ 60 years, tumor grade I-II, T1, luminal subtype, no lymph-vascular invasion, BCT, RT, chemotherapy and hormonal therapy were favorable factors of OS (P <0.05). Age > 60 years, tumor grade I-II, T1, one axillary lymph node metastasis, luminal subtype, BCT, RT and hormonal therapy were favorable factors of LRR (P <0.05). Multivariate analysis showed that age (p = 0.009), T stage (p <0.001), molecular subtype (p = 0.009) and chemotherapy (p <0.001) were independent prognostic factors for OS. RT (p = 0.054) and hormonal therapy (p = 0.063) had a trend to improve OS. Age (p = 0.034), T stage (p = 0.002), molecular subtype (p <0.001), RT (P = 0.001) and the number of positive axillary lymph node (P <0.001) were independent prognostic factors for LRR. The type of breast surgery had no significant effect on OS (p = 0.388) and LRR (p = 0.836). The type of breast surgery had no significant effect on the prognosis of patients with T1-2N1M0 breast cancer. Postoperative radiotherapy significantly reduces the risk of locoregional recurrence and might improve overall survival, suggesting that it may be required for majority of patients with mastectomy.

The Impact of Disparate Subtypes of Breast Cancer and Response to Postoperative Radiation Therapy in Neoadjuvant Setting

Neoadjuvant Radiotherapy Improves Overall Survival for T3/4N+M0 Rectal Cancer Patients: a Population-Based Study of 20300 Patients

Effects of Core Needle Biopsy and Subsequent Neoadjuvant Chemotherapy on Molecular Alterations and Outcome in Breast Cancer

Radiotherapy May Play an Important Role in Improving the Efficacy of Breast-Conserving Therapy Compared with Mastectomy in Patients with T1-2N1M0 Breast Cancer

Influence of Radiation Therapy on the Outcome of T1-2N0M0 Triple-Negative Breast Cancer: A SEER Population-Based Retrospective Analysis.

Impact of Postmastectomy Radiation Therapy on Breast Cancer Patients According to Pathologic Nodal Status after Modern Neoadjuvant Chemotherapy

Postmastectomy Radiotherapy After Neoadjuvant Chemotherapy in cT1-2N+ Breast Cancer Patients: A Single Center Experience and Review of Current Literature

The Role of Postmastectomy Radiation Therapy for Clinical Stage II-III Breast Cancer Patients with Pathological Complete Remission of Axillary Lymph Nodes after Neoadjuvant Chemotherapy

Impact of Adjuvant Chemotherapy on the Prognosis of Hormone Receptor Negative Breast Cancer with Residual Lymph Node Disease after Neoadjuvant Chemotherapy

The Role of Postmastectomy Radiation Therapy in Locally Advanced Breast Cancer Patients Treated with Neoadjuvant Chemotherapy and Mastectomy

Disscussion and analysis of the effect of adjuvant radiotherapy after neoadjuvant chemotherapy for stage T1-2N1M0 breast cancer

The effect of omission of adjuvant radiotherapy after neoadjuvant chemotherapy and breast conserving surgery with a pathologic complete response

Abstract P1-14-18: Postmastectomy Radiotherapy Improves the Outcomes of Stage III Breast Cancer Patients with Negative Lymph Nodes after Neoadjuvant Chemotherapy

Postmastectomy radiotherapy reduces locoregional and disease recurrence in patients with stage II-III triple-negative breast cancer treated with neoadjuvant chemotherapy and mastectomy.

Radiotherapy plays an important role in improving the survival outcome in patients with T1–2N1M0 breast cancer – a joint analysis of 4262 real world cases from two institutions

Radiotherapy Can Improve The Disease-Free Survival Rate In Triple-Negative Breast Cancer Patients With T1-T2 Disease And One To Three Positive Lymph Nodes After Mastectomy

Survival following radiotherapy in young women with localized early-stage breast cancer according to molecular subtypes.

The Impact of Neoadjuvant Chemotherapy on Patients With T1N0M0 Triple-Negative and HER-2 Positive Breast Cancer: A Retrospective Analysis Based on the SEER Database

The role of postmastectomy radiation in patients with ypN0 breast cancer after neoadjuvant chemotherapy: a meta-analysis

Outcomes in Patients with pT3N0M0 Breast Cancer with and without Postmastectomy Radiotherapy

Practical Model to Optimize the Strategy of Adjuvant Postmastectomy Radiotherapy in T1-2N1 Breast Cancer with Modern Systemic Therapy